Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK vs. Andrx Wellbutrin SR Appeal Turns On Role Of Excipient

Executive Summary

GlaxoSmithKline's Wellbutrin SR and Zyban patents do not cover the low-density form of the excipient HPMC used in Andrx' ANDA product, the generic company argued during a federal circuit appeals court hearing in Washington, D.C. Dec. 2

You may also be interested in...



Wellbutrin SR Patent Needs Further Review, Appeals Court Agrees With GSK

An appeals court ruling for GlaxoSmithKline in Wellbutrin SR patent litigation against Andrx finds the district court erred in its construction of GSK's patent claims

Wellbutrin SR Patent Needs Further Review, Appeals Court Agrees With GSK

An appeals court ruling for GlaxoSmithKline in Wellbutrin SR patent litigation against Andrx finds the district court erred in its construction of GSK's patent claims

Wellbutrin SR Patent Cases: Did GSK Surrender Claims To Excipients?

GlaxoSmithKline's patent infringement cases against Impax and Excel regarding Wellbutrin SR and Zyban appear to hinge on whether excipients used by the generic firms were "foreseeable.

Related Content

UsernamePublicRestriction

Register

PS040905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel